Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PAS 004

Next Previous
Drug Profile

PAS 004

Alternative Names: CIP-1374; CIP-137401; PAS-004

Latest Information Update: 11 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cheminpharma
  • Developer Cheminpharma; Pasithea Therapeutics
  • Class Antineoplastics; Macrocyclic compounds; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neurofibromatosis 1
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neurofibromatosis 1; Solid tumours
  • Preclinical Inflammation; Noonan syndrome

Most Recent Events

  • 02 Jun 2025 Updated efficacy, adverse events and pharmacodynamics data from a phase I trial in Solid tumours released by Pasithea Therapeutics
  • 30 May 2025 Pharmacodynamics data from preclinical trials in Inflammation released by Pasithea Therapeutics
  • 20 May 2025 Preclinical trials in Inflammation in USA (PO), before May 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top